CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Paris, France and 145 other locations
Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation phase receiving monotherapy CID-103. Once ...
Phase 1
Villejuif Cedex, France and 3 other locations
be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patientsThis is an open-label, multicenter, no...
Phase 2
Paris, France and 28 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
Paris, France and 40 other locations
CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...
Phase 2
Paris 10, France and 35 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Paris, France and 59 other locations
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
Paris, France and 211 other locations
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical ben...
Phase 4
Paris, France and 12 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Paris, France and 126 other locations
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...
Phase 1
Paris, France and 30 other locations
Clinical trials
Research sites
Resources
Legal